Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT3306 plus chemotherapy vs Keytruda plus chemotherapy in stage IV non-squamous NSCLC
2024-510640-32-00Phase 3Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Primary PK parameters and Confirmed best overall tumor response by BIRC per RECIST v1.1. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2024-510640-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510640-32-00.